THE European Medicines Agency (EMA) has suspended marketing of modified- or prolonged-release products containing paracetamol, around concerns of complexities in managing overdoses.
The recommendation was made by the agency's experts in medicines safety, the Pharmacovigilance Risk Assessment Committee, which highlighted that the advantages of a longer-acting product did not outweigh the complications of managing an overdose of the medicine.
The treatment procedures for immediate-release products were not necessarilly appropriate for modified-release paracetamol.
Not knowing which paracetamol form is involved in an overdose incident increases risks around the crisis management, the EMA said.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Dec 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Dec 17
